Comparative Pharmacology
Head-to-head clinical analysis: TYZEKA versus VITRAVENE PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TYZEKA versus VITRAVENE PRESERVATIVE FREE.
TYZEKA vs VITRAVENE PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Telbivudine is a synthetic thymidine nucleoside analogue with activity against hepatitis B virus (HBV). It is phosphorylated intracellularly to the active triphosphate form, which competes with natural thymidine triphosphate for incorporation into viral DNA, causing chain termination and inhibition of HBV DNA polymerase (reverse transcriptase).
Antisense oligonucleotide that binds to mRNA of human cytomegalovirus (HCMV), inhibiting viral replication by blocking protein synthesis.
600 mg orally once daily
Intravitreal injection: 330 mcg (0.05 mL of 6.6 mg/mL solution) every 2 weeks for 2 doses, then every 4 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 15 hours (range 12-20 hours) in patients with normal renal function; half-life is prolonged in renal impairment, requiring dose adjustment.
Terminal elimination half-life is approximately 2 hours in patients with normal renal function. In patients with renal impairment, half-life may be prolonged up to 10 hours.
Renal excretion of unchanged drug accounts for approximately 40% of the administered dose; biliary/fecal excretion accounts for approximately 60%.
Primarily renal excretion. Approximately 40% of the dose is excreted unchanged in urine within 24 hours. Biliary/fecal excretion accounts for less than 5%.
Category C
Category C
Antiviral, Hepatitis B
Antiviral